Topics
Health
Pharma
Biotech
Politics & Policy
Health Tech
In the Lab
Business
Artificial Intelligence
Opinion
First Opinion
The Pharmalot View
Adam’s Take
Podcast
Newsletters
Events
Upcoming Events
STAT Summit
Webinars
STAT Expert Advantage
Reports
Log in
Subscribe
Newsletters
Try STAT Plus
Newsletters
Try STAT Plus
The Pharmalot View
By
Ed Silverman
The Pharmalot View
The FDA commissioner sweepstakes: Is Azar yearning to get out of Gottlieb’s shadow?
By
Ed Silverman
The Pharmalot View
Memo to the Novartis CEO: When in doubt, give the FDA a heads-up
By
Ed Silverman
advertisement
The Pharmalot View
Trump proposes importing medicines, but he’s really seeking a quick political hit
By
Ed Silverman
advertisement
The Pharmalot View
Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant
By
Ed Silverman
The Pharmalot View
Kapoor certainly deserves to go to jail, but so do some other pharma execs
By
Ed Silverman
The Pharmalot View
If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients
By
Ed Silverman
The Pharmalot View
Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain
By
Ed Silverman
advertisement
The Pharmalot View
Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator
By
Ed Silverman
advertisement
The Pharmalot View
Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices
By
Ed Silverman
The Pharmalot View
The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?
By
Ed Silverman
The Pharmalot View
The list price is not right: Trump’s plan to force pharma to advertise prices is misguided
By
Ed Silverman
The Pharmalot View
One of the world’s largest drug makers is paying docs again — and patients are the worse off
By
Ed Silverman
The Pharmalot View
From zero to hero: J&J CEO praises Trump one year after chastising him
By
Ed Silverman
The Pharmalot View
When modest is actually excessive: AstraZeneca spins its price hikes
By
Ed Silverman
The Pharmalot View
He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices
By
Ed Silverman
The Pharmalot View
Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising
By
Ed Silverman
The Pharmalot View
Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines
By
Ed Silverman
The Pharmalot View
The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous
By
Ed Silverman
The Pharmalot View
California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference
By
Ed Silverman
The Pharmalot View
Here’s how a loophole in a transparency law can distort medical practices
By
Ed Silverman
The Pharmalot View
This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
By
Ed Silverman
The Pharmalot View
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
By
Ed Silverman
The Pharmalot View
Drug makers deserve to be publicly shamed for thwarting competition from generics
By
Ed Silverman
The Pharmalot View
The art of the deal? Why a money-back guarantee for drugs is a bad idea
By
Ed Silverman
The Pharmalot View
If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon
By
Ed Silverman
The Pharmalot View
It’s time to make it legal for Americans to order prescription drugs from abroad
By
Ed Silverman
The Pharmalot View
US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it
By
Ed Silverman
The Pharmalot View
The Trump administration could bring down drug prices. But it would take guts
By
Ed Silverman
The Pharmalot View
Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life
By
Ed Silverman
Next Page »
Your daily dose of news in health and medicine
Industry
Academia
Advertising/Marketing
Advocacy
Biotech
Consultancy/Firm
Financial Services
Government
Healthcare Payer
Healthcare Provider
Media
Medical Device
Non-profit
Pharma
Technology
Privacy Policy
Leave this field empty if you're human:
